Summary

At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Medical Director, Clinical Development to join the Regeneron Genetic Medicines Clinical Development Unit (RGM CDU), where you will serve as a clinical champion for genetic medicine programs from target nomination through human studies. In this role, you will shape how novel targets and modalities move into the clinic while collaborating with Research, the Regeneron Genetics Center, and cross-functional study teams. This position offers the opportunity to contribute to a fast-growing, science-driven organization making a meaningful difference to patients worldwide.

Job description

Build our future together

At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Medical Director, Clinical Development to join the Regeneron Genetic Medicines Clinical Development Unit (RGM CDU), where you will serve as a clinical champion for genetic medicine programs from target nomination through human studies. In this role, you will shape how novel targets and modalities move into the clinic while collaborating with Research, the Regeneron Genetics Center, and cross-functional study teams. This position offers the opportunity to contribute to a fast-growing, science-driven organization making a meaningful difference to patients worldwide.

When & where

Location: Tarrytown, NY
Work model/flexibility: 4 days/week
Travel percentage: 10% to relevant conferences

Discover your role

Serve as the clinical champion for research programs, from target nomination to clinical candidate selection
Provide clinical input on disease areas and indications, and evaluate novel targets and modalities
Partner with Research, the Regeneron Genetics Center, and external institutions on emerging targets and indications
Design first-in-human, proof-of-concept, and registrational studies with scientific rigor and medical relevance
Lead cross-functional study teams, providing medical leadership and driving timely, high-quality execution
Lead benefit-risk assessments and safety monitoring to protect patient safety
Identify trial, program, and data risks early and implement mitigation strategies
Build strong relationships with key investigators, external experts, and partner biotech teams

This role requires

M.D. or M.D./Ph.D. with Board Certification/Eligibility in neurology or psychiatry
1-3 years of clinical research experience in the pharmaceutical industry, or significant academic clinical trials/research experience
Authorship of peer-reviewed medical or scientific publications
Strong written and verbal communication and presentation skills
Sound critical thinking and decision-making in a fast-paced, collaborative environment

Requirements

M.D. or M.D./Ph.D. with Board Certification/Eligibility in neurology or psychiatry
1-3 years of clinical research experience in the pharmaceutical industry, or significant academic clinical trials/research experience
Authorship of peer-reviewed medical or scientific publications
Strong written and verbal communication and presentation skills
Sound critical thinking and decision-making in a fast-paced, collaborative environment

Benefits

Annual bonuses
Incentive plans
Equity awards
Pension or retirement benefits
401(k) company match
Health and wellness programs
Fitness centers
Medical insurance
Dental insurance
Vision insurance
Life insurance
Disability insurance
Paid time off
Family support benefits

Company overview

Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.